This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...

The progression of relapsing-onset multiple sclerosis (MS) and its associated disability may be slowing, results from a large population-based study suggest. In an evaluation of more than 7000 ...

More than 1 million people across the United States live with multiple sclerosis (MS), a disease that affects the brain, ...

Cantex and Headlamp Health are teaming up to accelerate the development of azeliragon for severe depression and fatigue in MS ...

Two complementary predictors (DAAE-M and ELIE) estimate individualized 5-year progression risk using routine clinical data, extending the prior DAAE framework beyond static baseline risk. Registry ...

“Our data add and expand previous observations on silent progression in MS and are consistent with the view of the disease as a single continuum, in which RAW [relapse-associated worsening] and PIRA ...

Significantly increased odds of confirmed disability progression were associated with the number of persisting pragmatic rim lesions. HealthDay News — Reducing or preventing paramagnetic rim lesions ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

The International Progressive MS Alliance announces the MS Clinical and Imaging Data Resource (MS CIDR) is now accepting ...